{
    "clinical_study": {
        "@rank": "48734", 
        "arm_group": [
            {
                "arm_group_label": "autologous purified CD34+ cell", 
                "arm_group_type": "Experimental", 
                "description": "transplantation of autologous purified CD34+ cell"
            }, 
            {
                "arm_group_label": "autologous PB-MNC", 
                "arm_group_type": "Active Comparator", 
                "description": "transplantation of autologous peripheral blood mononuclear cells"
            }
        ], 
        "brief_summary": {
            "textblock": "To compare the efficacy and cost-effectiveness between purified CD34+ cells and peripheral\n      blood mononuclear cells in treatment of critical limb ischemia"
        }, 
        "brief_title": "Purified CD34+ Cells Versus Peripheral Blood Mononuclear Cells in Treatment of Critical Limb Ischemia", 
        "completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Thromboangiitis Obliterans", 
            "Arteritis", 
            "Peripheral Arterial Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Arteritis", 
                "Ischemia", 
                "Thromboangiitis Obliterans", 
                "Peripheral Arterial Disease", 
                "Peripheral Vascular Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Rutherford scale of 4-5\n\n          -  thromboangiitis obliterans,  peripheral arterial disease, or arteritis caused by\n             other etiologies, such as collagen diseases\n\n          -  surgical or endovascular procedures are considered  unlikely to have successful\n             long-term revascularization, or have failed\n\n          -  more than 4 weeks of critical limb ischemia\n\n          -  if present, a non-healing ulcer after more than 4 weeks of optimal care by a wound\n             care physician and a nurse\n\n        Exclusion Criteria:\n\n          -  within 3 months of an acute myocardial infarction\n\n          -  any contraindication for the administration of granulocyte colony stimulating factor\n             (G-CSF)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02089828", 
            "org_study_id": "B2014-021"
        }, 
        "intervention": [
            {
                "arm_group_label": "autologous purified CD34+ cell", 
                "intervention_name": "autologous purified CD34+ cells", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "autologous PB-MNC", 
                "intervention_name": "autologous peripheral blood mononuclear cells", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 17, 2014", 
        "location": {
            "contact": {
                "email": "dzh926@126.com", 
                "last_name": "Zhihui Dong, M.D.", 
                "phone": "862164041990", 
                "phone_ext": "2904"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "zip": "200032"
                }, 
                "name": "Zhihui Dong"
            }, 
            "investigator": [
                {
                    "last_name": "Weiguo Fu, M.D.", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Zhihui Dong, M.D.", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized Control Trial on Purified CD34+ Cells Versus Peripheral Blood Mononuclear Cells in Treatment of Critical Limb Ischemia", 
        "other_outcome": {
            "measure": "improvement on peak pain-free walking time", 
            "safety_issue": "No", 
            "time_frame": "at 3 months"
        }, 
        "overall_contact": {
            "email": "dzh926@126.com", 
            "last_name": "Zhihui Dong, M.D.", 
            "phone": "862164041990", 
            "phone_ext": "2904"
        }, 
        "overall_official": [
            {
                "affiliation": "Fudan University", 
                "last_name": "Weiguo Fu, M.D.", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Fudan University", 
                "last_name": "Zhihui Dong, M.D.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "major-amputation-free survival rate", 
            "safety_issue": "No", 
            "time_frame": "at 6 months"
        }, 
        "reference": {
            "PMID": "23611711", 
            "citation": "Dong Z, Chen B, Fu W, Wang Y, Guo D, Wei Z, Xu X, Mendelsohn FO. Transplantation of purified CD34+ cells in the treatment of critical limb ischemia. J Vasc Surg. 2013 Aug;58(2):404-411.e3. doi: 10.1016/j.jvs.2013.01.037. Epub 2013 Apr 21."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02089828"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "improvement on transcutaneous partial oxygen pressure", 
            "safety_issue": "No", 
            "time_frame": "at 3 months"
        }, 
        "source": "Shanghai Zhongshan Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shanghai Zhongshan Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}